Alpha-Fetoprotein in Cancer Diagnosis

Sensitivity and Specificity

• Alpha-fetoprotein (AFP) has poor sensitivity ranging from 39% to 65% for hepatocellular carcinoma (HCC) diagnosis, with specificity ranging from 76% to 97% depending on the cut-off values used 1
• At the commonly used cut-off of 20 ng/ml, AFP shows good sensitivity but low specificity, while at higher cut-offs of 200 ng/ml, sensitivity drops significantly to only 22%, though specificity improves 2
• AFP is only elevated in 40-60% of HCC cases, particularly showing poor sensitivity in early-stage disease 3

Limitations as a Diagnostic Tool

• Many HCC patients exhibit normal AFP serum levels, particularly during early-stage disease, and AFP levels can be elevated in non-HCC patients, including those with non-cancerous chronic liver diseases, intrahepatic cholangiocarcinoma, and metastatic colon cancer 3
• Fluctuating levels of AFP in patients with cirrhosis might reflect flares of liver disease or HCC development, and only a small proportion of tumors at an early stage (10-20%) present with abnormal AFP serum levels 2

Clinical Applications and Guidelines

• Current clinical practice guidelines, including those from the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD), do not recommend AFP as a standalone test for the diagnosis of HCC due to concerns about sensitivity and specificity 3
• The National Comprehensive Cancer Network (NCCN) states that AFP may have utility for enhancing detection of HCC when used in combination with ultrasound in screening high-risk individuals 4
• When used in combination with ultrasound for surveillance, AFP levels only provide additional detection in 6-8% of cases not previously identified by ultrasound 2

Practical Considerations in AFP Testing

• At values over 200 IU/ml, AFP is more reliable as a tumor marker, but the percentage of patients with such high levels is very small 1
• AFP testing can be useful in conjunction with other test results to guide management when HCC is suspected, and an elevated AFP level in conjunction with imaging results showing a growing liver mass has high positive predictive value for HCC 5
• The diagnostic accuracy of absolute AFP cutoff values has not been validated, and values may vary by institution and patient population 5

AFP Elevation in HBsAg-Positive Patients

Surveillance and Diagnostic Strategies

• The American Association for the Study of Liver Diseases recommends ultrasound combined with AFP measurement every 6 months as the surveillance strategy for all HBsAg-positive patients, regardless of age, ALT levels, or apparent disease severity, which detects small HCC in 57-83% of cases 6
• AFP-based surveillance demonstrated a 37% reduction in HCC-related mortality in randomized controlled trials of HBsAg-positive patients, although the specific citation for this fact is not provided, a similar reduction is supported by 6
• At 20 ng/ml cutoff, sensitivity is 50-75% for small HCC, specificity is >90%, negative predictive value is >99%, and positive predictive value is only 9-30% in HBsAg-positive patients 6
• Rising AFP in a step-like manner strongly suggests HCC, even if absolute values remain below 200 ng/ml, in HBsAg-positive patients 6
• Persistent mild elevation (>200 ng/ml) indicates higher HCC risk than single elevated values in HBsAg-positive patients 6
• Men ≥45 years of age, patients with cirrhosis, family history of HCC, and even younger patients without cirrhosis require intensive surveillance for HCC, as supported by 6

Hepatocarcinoma Screening and Diagnosis

Primary Recommendations

• The American Association for the Study of Liver Diseases (AASLD) recommends ultrasound combined with alpha-fetoprotein (AFP) measurement every 6 months for surveillance in patients with suspected hepatocarcinoma and chronic liver disease or cirrhosis, with AFP ≥200 ng/mL plus typical imaging features on dynamic CT or MRI allowing diagnosis without biopsy 7, 8

Target Populations Requiring Screening

• The American Association for the Study of Liver Diseases (AASLD) recommends screening for cirrhotic patients of any etiology, including hepatitis B, hepatitis C, NASH, alcoholic cirrhosis, primary biliary cholangitis, genetic hemochromatosis, and alpha-1 antitrypsin deficiency 7
• The American Association for the Study of Liver Diseases (AASLD) recommends screening for chronic hepatitis B carriers, regardless of cirrhosis status, particularly Asian men >40 years, Asian women >50 years, those with family history of HCC, and African/North American blacks 7

Recommended Screening Tests

• The Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) recommends the optimal surveillance approach combining ultrasound with AFP measurement every 6 months, which increases early-stage HCC detection from 45% to 63% compared to ultrasound alone 7, 9
• The Asian Pacific Association for the Study of the Liver (APASL) recommends mandatory combination of ultrasound plus AFP due to higher HCC prevalence in these regions 7, 9

Diagnostic Algorithm for Detected Liver Nodules

• The American Association for the Study of Liver Diseases (AASLD) recommends proceeding to dynamic contrast-enhanced CT or MRI looking for typical HCC features for nodules ≥1 cm on surveillance ultrasound 7, 10, 11
• The American Association for the Study of Liver Diseases (AASLD) recommends diagnosing HCC without biopsy in cirrhotic patients with AFP ≥200 ng/mL and typical imaging features on dynamic CT or MRI 8, 10

Alpha-Fetoprotein (AFP) as a Tumor Marker

• The American Association for the Study of Liver Diseases (AASLD) recommends an AFP diagnostic threshold of ≥200 ng/mL, with sensitivity of 22-36% and specificity of 97-99% for HCC detection 8
• The American Association for the Study of Liver Diseases (AASLD) recommends monitoring for progressive AFP elevation ≥7 ng/mL/month, which has 71.4% sensitivity and 100% specificity for HCC diagnosis 12

Pitfalls to Avoid

• The American Association for the Study of Liver Diseases (AASLD) recommends not relying on AFP alone for HCC screening or diagnosis due to poor sensitivity, and always combining with imaging 7, 9
• The American Association for the Study of Liver Diseases (AASLD) recommends not dismissing normal AFP, as up to 46% of HCC patients have completely normal AFP (<20 ng/mL), requiring imaging-based diagnosis 7, 9
• The American Association for the Study of Liver Diseases (AASLD) recommends not ignoring AFP trends, as a rising AFP, even below diagnostic thresholds, is virtually diagnostic of HCC 12

Diagnostic Accuracy of Alpha-Fetoprotein for Hepatocellular Carcinoma

Sensitivity and Specificity

• The National Comprehensive Cancer Network recommends that at a 20 ng/mL cutoff, Alpha-Fetoprotein has a sensitivity of 41-70% and specificity of 80-94% for diagnosing Hepatocellular Carcinoma, missing 30-59% of cases 13, 14
• At the same 20 ng/mL cutoff, the sensitivity of Alpha-Fetoprotein for early-stage Hepatocellular Carcinoma drops to 32-50% 13, 14
• The American Gastroenterological Association notes that at a 100 ng/mL cutoff, Alpha-Fetoprotein has a sensitivity of 31% and specificity of 99% for diagnosing Hepatocellular Carcinoma, missing 69% of cases 13

Guideline-Based Recommendations

• The National Comprehensive Cancer Network and Asian guidelines recommend combining ultrasound with Alpha-Fetoprotein measurement every 6 months for surveillance in high-risk populations, such as those with cirrhosis or chronic hepatitis B, as this combination increases early-stage Hepatocellular Carcinoma detection from 45% to 63% compared to ultrasound alone 13, 14

Comparative Accuracy

• Ultrasound alone detects Hepatocellular Carcinoma with 84% sensitivity, compared to Alpha-Fetoprotein's 69% at 20 ng/mL cutoff, but combining both modalities increases detection to 92% 13
• The American Gastroenterological Association found that abbreviated MRI showed 90% sensitivity and 89% specificity for early Hepatocellular Carcinoma, substantially outperforming Alpha-Fetoprotein's 50% sensitivity and 67% specificity 14

Serum Alpha‑Fetoprotein (AFP) Surveillance in Cirrhotic Patients

Guideline Recommendations

Diagnostic Performance of Surveillance Modalities

Interpretation of Elevated AFP During Surveillance

Conditions That May Cause False‑Positive AFP Elevations

International Guideline Comparisons

Overall Clinical Impact

AFP in Hepatocellular Carcinoma (HCC) Surveillance

Evidence‑Supported Clinical Use

• In patients with cirrhosis or chronic hepatitis B infection, surveillance with ultrasound plus serum AFP every 6 months improves early‑stage HCC detection and is the most evidence‑backed application of AFP testing. 18

Guideline Recommendations

• Western societies (American Association for the Study of Liver Diseases – AASLD; European Association for the Study of the Liver – EASL) advise ultrasound‑based HCC surveillance and list AFP as an optional adjunct, citing limited incremental benefit. 18
• Asian societies and the 2024 British Society of Gastroenterology require the combined ultrasound + AFP approach for routine surveillance in high‑prevalence regions. 18

Cost‑Effectiveness and Incremental Detection

• Analyses from Western health systems show that adding AFP to ultrasound yields only a 6–8 % increase in detection of HCC while raising surveillance costs by roughly 80 %, influencing the optional status of AFP. 19
• Asian health‑economic evaluations argue that the substantial sensitivity gain from combined testing justifies its routine use in populations with higher HCC incidence. 19

Sensitivity and Specificity in Early‑Stage Disease

• When the diagnostic AFP threshold is set at 200 ng/mL, sensitivity falls to ≈22 % while specificity approaches 100 %, underscoring poor performance for early‑stage tumors. 19
• Only 10–20 % of early‑stage HCCs exhibit elevated AFP levels, limiting its utility as a solitary early‑detection marker. 20

High‑Risk Populations Requiring Surveillance

• Surveillance is recommended for all cirrhotic patients (any etiology), chronic hepatitis B carriers (Asian men ≥ 40 y, Asian women ≥ 50 y, or any carrier with a family history of HCC), chronic hepatitis C patients, and those with NAFLD‑related cirrhosis. 18

Imaging Trigger Criteria

• Detection of a ≥ 1 cm hepatic nodule on ultrasound mandates immediate diagnostic imaging (dynamic contrast‑enhanced CT or MRI) regardless of AFP level. 19

Japanese Guidelines on Complementary Biomarkers

• The Japanese Society of Hepatology recommends a combined panel of AFP, PIVKA‑II (des‑γ‑carboxy prothrombin), and AFP‑L3 for HCC surveillance. [20][18]
• Within this panel, an AFP‑L3 fraction > 15 % together with AFP > 200 ng/mL or PIVKA‑II > 40 mAU/mL is stipulated as a diagnostic criterion for HCC. [20][18]
• AFP‑L3 is reported to be more specific than total AFP for HCC, although its validation remains limited outside Asia. 20